Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | JAK1 | P23458 | 2/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.41 |
| ▸ | WDR5 | P61964 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 5/20 | 0.40 |
| ▸ | AKT2 | P31751 | 5/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | TNKS | O95271 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5200249 | 0.91 | CNR1 (0.41) | JAK2JAK1PDE4BWDR5CNR1 | |
| SCHEMBL5907462 | 0.86 | TGFBR1 (0.55) | JAK2JAK1PDE4BTGFBR1HRH3 | |
| SCHEMBL5200014 | 0.84 | TGFBR1 (0.53) | JAK2JAK1TYK2JAK3TGFBR1 | |
| SCHEMBL5198540 | 0.83 | TGFBR1 (0.39) | JAK2JAK1CNR1CNR2TYK2 | |
| SCHEMBL5201329 | 0.82 | TGFBR1 (0.36) | JAK2JAK1TYK2JAK3TGFBR1 | |
| SCHEMBL5199891 | 0.81 | CNR2 (0.49) | CNR2TGFBR1 | |
| SCHEMBL5198175 | 0.81 | BMPR1A (0.45) | CNR1CNR2TGFBR1HRH3 | |
| SCHEMBL5232325 | 0.80 | CYP2D6 (0.42) | CNR1TGFBR1 | |
| SCHEMBL5201014 | 0.79 | TGFBR1 (0.46) | JAK2JAK1CNR1CNR2TGFBR1 | |
| SCHEMBL5199156 | 0.79 | MEN1 (0.40) | TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275968-A1 | Substituted Biphenyl Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1798229-A1 | SUBSTITUTED BIPHENYL DERIVATIVE | Sankyo Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275968-A1 | Substituted Biphenyl Derivative | COL2A1, COL1A1, FGFR3 | JAK2 21/4885JAK1 1663/4885PDE4B 2470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.